Immunotherapy research for prostate cancer from 2000 to 2024: a bibliometric and visualization analysis
Prostate cancer immunotherapy has shifted from single-agent exploration to multimodal strategies. Future priorities include overcoming "cold tumor" barriers and developing novel immune-based combination approaches.
Authors
- Tao Wu (ORCID: https://orcid.org/0000-0002-0629-8421)
- Kai Ye (ORCID: https://orcid.org/0009-0006-0086-0440)
- Chengde Ren
- Mingqing Dong (ORCID: https://orcid.org/0000-0001-9720-535X)
- Bingyun Li (ORCID: https://orcid.org/0000-0002-5766-5666)
- Jian Wang (ORCID: https://orcid.org/0000-0002-5335-8845)
Institutions
- Qinghai University Affiliated Hospital (CN)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tau-2025-414
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00